Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cisplatin spinal tumor slow-release implant and preparation method thereof

A technology for slow-release implants and spinal tumors, which is applied in the direction of anti-tumor drugs, pharmaceutical formulations, and medical preparations of non-active ingredients, etc. The effect of survival time

Inactive Publication Date: 2010-06-16
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The curative effect of traditional systemic intravenous chemotherapy is often unsatisfactory: the inability of the drug to concentrate locally in the tumor, the short duration of action on the tumor, the large systemic side effects, the toxicity to normal tissue cells, and the instability of the drug in the body are the reasons for the reduced curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cisplatin spinal tumor slow-release implant and preparation method thereof
  • Cisplatin spinal tumor slow-release implant and preparation method thereof
  • Cisplatin spinal tumor slow-release implant and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] prescription:

[0022] Cisplatin: PLGA 30:70 (weight ratio)

[0023] PLGA concentration is 40% (50:50)

[0024] Oil phase solvent Dichloromethane

[0025] Emulsifier Polyvinyl alcohol

[0026] Accurately weigh 300 mg of cisplatin, dissolve it in an appropriate amount of double-distilled water, and use it as the inner water phase. Accurately weigh 700 mg of PLGA, dissolve in an appropriate amount of dichloromethane, and use it as the oil phase. The oil phase is added to the inner water phase under the condition of avoiding light and ultrasonication in an ice-water bath to obtain colostrum. Quickly add this colostrum into the polyvinyl alcohol solution; ultrasonically treat until the double emulsion is formed; then add the resulting double milk into the low-concentration polyvinyl alcohol solution. Remove dichloromethane by volatilization; collect the microspheres by centrifugation, wash with distilled water 3 times; add double distilled water to make a suspension, a...

Embodiment 2

[0028] prescription:

[0029] Cisplatin: PLGA 25:75 (weight ratio)

[0030] PLGA concentration is 15% (75:25)

[0031] Oil phase solvent Dichloromethane

[0032] Emulsifier methyl cellulose

[0033] Accurately weigh 250 mg of cisplatin, dissolve it in an appropriate amount of double-distilled water, and use it as the inner water phase. Accurately weigh 750 mg of PLGA, dissolve in an appropriate amount of dichloromethane, and use it as the oil phase. The oil phase is added to the inner water phase under the condition of avoiding light and ultrasonication in an ice-water bath to obtain colostrum. This colostrum is quickly added to the methylcellulose solution; sonicated until the double emulsion is formed; then the resulting double emulsion is added to the low-concentration methylcellulose. The subsequent preparation process was the same as in Example 1 to prepare a cisplatin sustained-release implant.

Embodiment 3

[0035] prescription:

[0036] Cisplatin: PLGA 20:80 (weight ratio)

[0037] PLGA concentration is 30% (50:50)

[0038] Oil phase solvent Dichloromethane

[0039] Emulsifier Polyvinyl alcohol

[0040] Accurately weigh 200 mg of cisplatin, dissolve it in an appropriate amount of double-distilled water, and use it as the inner water phase. Accurately weigh 800 mg of PLGA, dissolve in an appropriate amount of dichloromethane, and use it as the oil phase. The oil phase is added to the inner water phase under the condition of avoiding light and ultrasonication in an ice-water bath to obtain colostrum. The colostrum is quickly added to the polyvinyl alcohol solution; sonicated until the double emulsion is formed; then the resulting double emulsion is added to the low-concentration polyvinyl alcohol. The subsequent preparation process was the same as in Example 1 to prepare a cisplatin sustained-release implant.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmacy, and relates to a controlled-release medicinal preparation, in particular to a cisplatin spinal tumor slow-release implant which takes polylactic acid-glycolic acid copolymer (PLGA) as a carrier and cisplatin as a main medicament for treating the spinal tumor and a preparation method thereof. The weight ratio of the cisplatin to the PLGA is 1:99-40:60. A cisplatin slow-release micro-ball is prepared through reemulsifying-solvent volatilization method, and the micro-ball is tabletted to obtain the cisplatin slow-release implant for interstitial chemotherapty after the spinal tumor and the other tumor surgeries. Experiments prove that: the cumulative medicament release rate of the cisplatin slow-release implant after 38 days can reach 84 percent, the sustained release time in the body can reach 36 days, the local medicament concentration is high and an effect of inhibiting the tumor is obvious.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to controlled and sustained-release pharmaceutical preparations, in particular to a cisplatin sustained-release implant for treating spinal tumors with polylactic acid-glycolic acid copolymer (PLGA) as a carrier and cisplatin as the main agent. Preparation. Background technique [0002] Spinal tumor is a relatively special disease among various tumors. With the development and progress of social economy, the incidence and diagnosis rate of spinal tumors are increasing year by year. However, due to the particularity of the anatomical structure of the spine, the complexity of adjacent structures, and the local invasion of spinal tumors, it is extremely difficult to completely and fully remove the tumor tissue, and recurrence or metastasis often occurs after surgery. Therefore, how to prolong the postoperative survival period and improve the quality of life of patients with spinal tumors is sti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K33/24A61K47/34A61K9/00A61P35/00
Inventor 吴娟郑伟唐辉肖建如
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com